Skip to main content
. 2015 Apr 6;4(4):e001793. doi: 10.1161/JAHA.115.001793

Table 3.

Antiarrhythmic Medication Use

Frequency Mean Duration (Months)
GD Group NGD Group GD Group NGD Group
First prescribed antiarrhythmic medication
N 3056 2920 30.3 21.8
Flecainide 454 (14.9%) 91 (3.1%) 32.0 24.6
Propafenone 297 (9.7%) 99 (3.4%) 32.0 26.8
Amiodarone 749 (24.5%) 1517 (52.0%) 22.3 20.4
Dofetilide 245 (8.0%) 294 (10.1%) 34.3 31.6
Sotalol 1311 (42.9%) 407 (13.9%) 33.1 26.1
Dronedarone 0 488 (16.7%) 15.1
Disopyramide 0 15 (0.5%) 21.3
Procainamide 0 4 (0.1%) 16.7
Quinidine 0 5 (0.2%) 24.7
P value <0.001 <0.001
Second prescribed antiarrhythmic medication
N 562 (18.4%) 794 (27.2%) 19.5 15.8
Flecainide 82 (14.6%) 77 (9.7%) 23.5 16.8
Propafenone 30 (5.3%) 36 (4.5%) 21.8 17.8
Amiodarone 226 (40.2%) 213 (26.8%) 14.8 14.8
Dofetilide 169 (30.1%) 114 (14.4%) 23.8 15.9
Sotalol 55 (9.8%) 173 (21.8%) 18.2 18.1
Dronedarone 0 172 (21.7%) 14.2
Disopyramide 0 6 (0.8%) 12.0
Procainamide 0 2 (0.3%) 14.6
Quinidine 0 1 (0.1%) 5.7
P value <0.001 <0.001

GD indicates guideline‐directed group; NGD, non–guideline directed group.